Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)
NCT ID: NCT05529524
Last Updated: 2025-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
6 participants
OBSERVATIONAL
2022-11-07
2024-01-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).
NCT07191249
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT06284122
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
NCT05389293
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
NCT03789240
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
study population involves patients participating to CELESTIMO study in France. 10 sites are expected in this biobanking protocol study
Biological samples will collected as part of routine care (tissue and blood already sampled in routine and/or CELESTIMO study) at screening, at C4, at C12 or at progressive disease/relapse.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roche Pharma AG
INDUSTRY
The Lymphoma Academic Research Organisation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Camille Laurent, MD
Role: PRINCIPAL_INVESTIGATOR
Oncopole - Toulouse France
Karin Tarte, PhD
Role: PRINCIPAL_INVESTIGATOR
Micro-environnement et cancer (MICA) - Rennes France
Franck MORSCHHAUSER, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Lille - Lille France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier de La Cote Basque; Hematologie
Bayonne, , France
Hopital Claude Huriez; Hematologie
Lille, , France
Institut Paoli Calmettes
Marseille, , France
CHU Saint Eloi; Service d'Hématologie Clinique
Montpellier, , France
CHU NANTES - Hôtel Dieu; Service d'Hematologie Clinique
Nantes, , France
CHU de Nîmes - Hôpital Carémeau
Nîmes, , France
Hopital Saint Antoine; Hematologie Clinique
Paris, , France
Hopital De La Miletrie; Hematologie Et Oncologie Medicale
Poitiers, , France
CHU Pontchaillou
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CALC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.